Related references
Note: Only part of the references are listed.The Physiology and Pathology of Inositide Signaling in the Nucleus
Giulia Ramazzotti et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
Guillermo Garcia-Manero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes
M. Y. Follo et al.
LEUKEMIA (2011)
216 Azacitidine low-dose schedule in low-risk myelodysplastic syndromes. Clinical results of a multicenter phase II study
C. Fill et al.
LEUKEMIA RESEARCH (2011)
Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes
Pellegrino Musto et al.
CANCER (2010)
Molecular mechanisms involved in the progression of myelodysplastic syndrome
Florian Nolte et al.
FUTURE ONCOLOGY (2010)
Epigenetic Changes in the Myelodysplastic Syndrome
Jean-Pierre Issa
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
Therapy with azanucleosides for myelodysplastic syndromes
Alfonso Quintas-Cardama et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
The context and potential of epigenetics in oncology
J. Lopez et al.
BRITISH JOURNAL OF CANCER (2009)
DNA methylation and methyl-CpG binding proteins: developmental requirements and function
Ozren Bogdanovic et al.
CHROMOSOMA (2009)
Phosphoinositide-Phospholipase C β1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia
Matilde Y. Follo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
Matilde Y. Follo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Requirement of c-Myb for p210BCR/ABL-dependent transformation of hematopoietic progenitors and leukemogenesis
Maria Rosa Lidonnici et al.
BLOOD (2008)
Nuclear phospholipase C beta1 and cellular differentiation
Irene Faenza et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Lipid signalling in disease
Matthias P. Wymann et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
PI-PLC beta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes
M. Y. Follo et al.
LEUKEMIA (2008)
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation
Matilde Y. Follo et al.
CANCER RESEARCH (2007)
Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter
Irene Faenza et al.
ENDOCRINOLOGY (2007)
Protein kinase C and other diacylglycerol effectors in cancer
Erin M. Griner et al.
NATURE REVIEWS CANCER (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
A unique function for cyclin D3 in early B cell development
AB Cooper et al.
NATURE IMMUNOLOGY (2006)
Genomic DNA methylation: the mark and its mediators
RJ Klose et al.
TRENDS IN BIOCHEMICAL SCIENCES (2006)
Methyl-CpG-binding proteins in cancer: blaming the DNA methylation messenger
E Ballestar et al.
BIOCHEMISTRY AND CELL BIOLOGY (2005)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Cell cycle control genes and hematopoietic cell differentiation
Y Furukawa
LEUKEMIA & LYMPHOMA (2002)
TRANSFAC: an integrated system for gene expression regulation
E Wingender et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
